Angiopoietin-like-4, a potential target of tacrolimus, predicts earlier podocyte injury in minimal change disease

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Li, Jian Si ^a   Chen, Xiao ^a   Peng, Lei ^a,b   Wei, Shi Yao ^a   Zhao, Shi Lei ^a   Diao, Tian Tian ^a   He, Yi Xin ^a   Liu, Fang ^a   Wei, Qiu Ju ^a   Zhang, Qing Fang ^a   Li, Bing ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN LIKE 4; DESMIN; DOXORUBICIN; TACROLIMUS; UNCLASSIFIED DRUG; ANGPTL4 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL REGENERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EARLY DIAGNOSIS; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; MALE; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; NONHUMAN; PODOCYTE INJURY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; UPREGULATION; ANIMAL; BIOSYNTHESIS; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENETICS; GLOMERULUS; METABOLISM; NEPHROSIS, LIPOID; PATHOLOGY; PODOCYTE;

ANGIOPOIETINS; ANIMALS; DISEASE MODELS, ANIMAL; DOXORUBICIN; HUMANS; KIDNEY GLOMERULUS; NEPHROSIS, LIPOID; PODOCYTES; PROTEINURIA; RATS; TACROLIMUS;

EID: 84944735709     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137049     Document Type: Article

References (37)

1. Orth SR, Ritz E. The nephrotic syndrome. The New England journal of medicine. 1998; 338(17):1202-11. doi: 10.1056/NEJM199804233381707 PMID: 9554862.
2. Brenner BM, Rector FC. Brenner & Rector's the kidney. 8th ed. Philadelphia: Saunders Elsevier; 2008.
3. Habashy D, Hodson EM, Craig JC. Interventions for steroid-resistant nephrotic syndrome: a systematic review. Pediatric nephrology. 2003; 18(9):906-12. doi: 10.1007/s00467-003-1207-0 PMID: 12836096.
4. Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clinical journal of the American Society of Nephrology: CJASN. 2007; 2(3):445-53. doi: 10.2215/CJN.03531006 PMID: 17699450.
5. Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends in cell biology. 2007; 17(9):428-37. doi: 10.1016/j.tcb.2007.06.006 PMID: 17804239.
6. Yoshida K, Shimizugawa T, Ono M, Furukawa H. Angiopoietin-like protein 4 is a potent hyperlipidemiainducing factor in mice and inhibitor of lipoprotein lipase. Journal of lipid research. 2002; 43(11):1770-2. PMID: 12401877.
7. Ge H, Yang G, Yu X, Pourbahrami T, Li C. Oligomerization state-dependent hyperlipidemic effect of angiopoietin-like protein 4. Journal of lipid research. 2004; 45(11):2071-9. doi: 10.1194/jlr.M400138- JLR200 PMID: 15292369.
8. Yoon JC, Chickering TW, Rosen ED, Dussault B, Qin Y, Soukas A, et al. Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Molecular and cellular biology. 2000; 20(14):5343-9. PMID: 10866690; PubMed Central PMCID: PMC85983.
9. Kersten S, Mandard S, Tan NS, Escher P, Metzger D, Chambon P, et al. Characterization of the fasting- induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. The Journal of biological chemistry. 2000; 275(37):28488-93. doi: 10.1074/jbc.M004029200 PMID: 10862772.
10. Clement LC, Avila-Casado C, Mace C, Soria E, Bakker WW, Kersten S, et al. Podocyte-secreted angiopoietin- like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nature medicine. 2011; 17(1):117-22. doi: 10.1038/nm.2261 PMID: 21151138; PubMed Central PMCID: PMC3021185.
11. Peng L, Ma J, Cui R, Chen X, Wei SY, Wei QJ, et al. The calcineurin inhibitor tacrolimus reduces proteinuria in membranous nephropathy accompanied by a decrease in angiopoietin-like-4. PloS one. 2014; 9(8):e106164. doi: 10.1371/journal.pone.0106164 PMID: 25165975; PubMed Central PMCID: PMC4148427.
12. Ma J, Chen X, Li JS, Peng L, Wei SY, Zhao SL, et al. Upregulation of podocyte-secreted angiopoietinlike- 4 in diabetic nephropathy. Endocrine. 2014. doi: 10.1007/s12020-014-0486-5 PMID: 25424436.
13. Yaoita E, Kawasaki K, Yamamoto T, Kihara I. Variable expression of desmin in rat glomerular epithelial cells. The American journal of pathology. 1990; 136(4):899-908. PMID: 2183627; PubMed Central PMCID: PMC1877632.
14. Hoshi S, Shu Y, Yoshida F, Inagaki T, Sonoda J, Watanabe T, et al. Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Laboratory investigation; a journal of technical methods and pathology. 2002; 82(1):25-35. PMID: 11796823.
15. Mundel P, Heid HW, Mundel TM, Kruger M, Reiser J, Kriz W. Synaptopodin: an actin-associated protein in telencephalic dendrites and renal podocytes. The Journal of cell biology. 1997; 139(1):193-204. PMID: 9314539; PubMed Central PMCID: PMC2139823.
16. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nature medicine. 2008; 14(9):931-8. doi: 10.1038/nm.1857 PMID: 18724379; PubMed Central PMCID: PMC4109287.
17. Li H, Rao A, Hogan PG. Interaction of calcineurin with substrates and targeting proteins. Trends in cell biology. 2011; 21(2):91-103. doi: 10.1016/j.tcb.2010.09.011 PMID: 21115349; PubMed Central PMCID: PMC3244350.
18. Hoorn EJ, Walsh SB, McCormick JA, Furstenberg A, Yang CL, Roeschel T, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nature medicine. 2011; 17(10):1304-9. doi: 10.1038/nm.2497 PMID: 21963515; PubMed Central PMCID: PMC3192268.
19. Ozbay LA, Moller N, Juhl C, Bjerre M, Carstens J, Rungby J, et al. Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers. British journal of clinical pharmacology. 2012; 73(4):536-45. doi: 10.1111/j.1365-2125.2011.04118.x PMID: 21988494; PubMed Central PMCID: PMC3376430.
20. Fan L, Liu Q, Liao Y, Li Z, Ji Y, Yang Z, et al. Tacrolimus is an alternative therapy option for the treatment of adult steroid-resistant nephrotic syndrome: a prospective, multicenter clinical trial. International urology and nephrology. 2013; 45(2):459-68. doi: 10.1007/s11255-012-0205-1 PMID: 22684795.
21. Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J, et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney international. 2012; 82(10):1130-5. doi: 10.1038/ki.2012. 238 PMID: 22763815.
22. Okuda S, Oh Y, Tsuruda H, Onoyama K, Fujimi S, Fujishima M. Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney international. 1986; 29(2):502-10. PMID: 3486312.
23. Nephrol Dial TransplantBertani T, Poggi A, Pozzoni R, Delaini F, Sacchi G, Thoua Y, et al. Adriamycininduced nephrotic syndrome in rats: sequence of pathologic events. Laboratory investigation; a journal of technical methods and pathology. 1982; 46(1):16-23. PMID: 6172662.
24. Li B, Morioka T, Uchiyama M, Oite T. Bone marrow cell infusion ameliorates progressive glomerulosclerosis in an experimental rat model. Kidney international. 2006; 69(2):323-30. doi: 10.1038/sj.ki. 5000083 PMID: 16408122.
25. Canaud G, Bienaime F, Viau A, Treins C, Baron W, Nguyen C, et al. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nature medicine. 2013; 19(10):1288-96. doi: 10.1038/nm.3313 PMID: 24056770.
26. Li B, Cohen A, Hudson TE, Motlagh D, Amrani DL, Duffield JS. Mobilized human hematopoietic stem/ progenitor cells promote kidney repair after ischemia/reperfusion injury. Circulation. 2010; 121 (20):2211-20. doi: 10.1161/CIRCULATIONAHA.109.928796 PMID: 20458011; PubMed Central PMCID: PMC2919223.
27. Lin SL, Li B, Rao S, Yeo EJ, Hudson TE, Nowlin BT, et al. Macrophage Wnt7b is critical for kidney repair and regeneration. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(9):4194-9. doi: 10.1073/pnas.0912228107 PMID: 20160075; PubMed Central PMCID: PMC2840080.
28. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nature protocols. 2008; 3(6):1101-8. PMID: 18546601.
29. Li X, Li H, Ye H, Li Q, He X, Zhang X, et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide- resistant nephrotic syndrome and normal or mildly reduced GFR. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2009; 54(1):51-8. doi: 10.1053/j.ajkd. 2009.02.018 PMID: 19406543.
30. Zhang Q, Shi SF, Zhu L, Lv JC, Liu LJ, Chen YQ, et al. Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy. American journal of nephrology. 2012; 35(4):312-20. doi: 10.1159/000337175 PMID: 22456060.
31. Clement LC, Mace C, Avila-Casado C, Joles JA, Kersten S, Chugh SS. Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nature medicine. 2014; 20(1):37-46. doi: 10.1038/nm.3396 PMID: 24317117.
32. Belanger AJ, Lu H, Date T, Liu LX, Vincent KA, Akita GY, et al. Hypoxia up-regulates expression of peroxisome proliferator-activated receptor gamma angiopoietin-related gene (PGAR) in cardiomyocytes: role of hypoxia inducible factor 1alpha. Journal of molecular and cellular cardiology. 2002; 34(7):765-74. PMID: 12099716.
33. Glynne R, Akkaraju S, Healy JI, Rayner J, Goodnow CC, Mack DH. How self-tolerance and the immunosuppressive drug FK506 prevent B-cell mitogenesis. Nature. 2000; 403(6770):672-6. doi: 10.1038/ 35001102 PMID: 10688206.
34. Presser D, Sester U, Mohrbach J, Janssen M, Kohler H, Sester M. Differential kinetics of effector and regulatory T cells in patients on calcineurin inhibitor-based drug regimens. Kidney international. 2009; 76(5):557-66. doi: 10.1038/ki.2009.198 PMID: 19494797.
35. Kitahara K, Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Current opinion in rheumatology. 2007; 19(3):238-45. doi: 10.1097/BOR.0b013e328099af80 PMID: 17414949.
36. Penninga L, Moller CH, Gustafsson F, Steinbruchel DA, Gluud C. Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. European journal of clinical pharmacology. 2010; 66 (12):1177-87. doi: 10.1007/s00228-010-0902-6 PMID: 20882273.
37. Massella L, Muda AO, Legato A, Di Zazzo G, Giannakakis K, Emma F. Cyclosporine A treatment in patients with Alport syndrome: a single-center experience. Pediatric nephrology. 2010; 25(7):1269-75. doi: 10.1007/s00467-010-1484-3 PMID: 20238228.